Demystifying End-to-End DNA Sequencing Solutions

alt text
Presented by
Jonathan J. Keats, PhD
Jonathan J. Keats, PhD
Translational Genomics Research Institute (TGen)
RECORDED AT AMP 2022

Covered in this Webinar
Current diagnostic tools need scalable library preparation and target enrichment workflows to enhance biomarker detection
Targeted sequencing is a cost-effective approach to identifying low-abundance alleles for cancer diagnostics
Twist’s methylation capture workflow can boost your efforts to identify epigenetic biomarkers genomic signatures

With the rapid growth and availability of next-generation sequencing has come the need for efficient target enrichment solutions across multiple applications.  Targeted sequencing maximizes testing resources by selectively narrowing sequencing output to only your regions of interest, enabling increased depth per sample and limiting cost.  As we move into the genomics era, flexible and scalable library preparation and target enrichment workflows are critical to meet the expanding diagnostic landscape. Twist continues to provide innovative NGS solutions to empower researchers; from assay development tools such as our cfDNA Pan-Cancer Reference Standards to rare variant allele detection with our Unique Molecular Identifiers (UMI).  Comprehensive identification and study of methylation biomarkers can be performed with Twist’s highly efficient methylation capture workflow.  In order to support the growing clinically relevant variants for developing NGS-based assays, Twist MRD Twist MRD Rapid 500 Panels provide researchers with customized NGS tests in as little as six business days.  

 

In this workshop from AMP 2022, Shawn Gorda, Senior Staff Product Manager at Twist Biosciences, showcases Twist’s diverse selection of target enrichment and library preparation pipelines for NGS. He is then joined by Jonathan Keats, Assistant Professor in the Integrated Cancer Genomics Division at the Translational Genomics Research Institute (TGen), who will demonstrate how he used Twist’s UMIs and Library Preparation EF 2.0 to identify novel genetic biomarkers in multiple myeloma patients.

 

For Research Use Only. Not for use in diagnostic procedures.

 

Share your details to Watch the Webinar